Drew Holzapfel

Executive Director, Global CEO Initiative on Alzheimer’s Disease

Drew Holzapfel is the Executive Director of the Global CEO Initiative on Alzheimer’s Disease, a coalition of leading corporations investing in Alzheimer’s disease research, treatment, and care. He is also a Partner at High Lantern Group, a healthcare consultancy focused on the intersection of business strategy and public policy. Mr. Holzapfel brings nearly two decades of healthcare experience in government and corporate affairs, sales, and marketing in global biotechnology, pharmaceutical, and U.S. government organizations to a diverse client base. He has spent over 10 years working on Alzheimer’s disease in a range of positions. Prior to joining High Lantern Group, Mr. Holzapfel was at Pfizer, where he most recently led efforts around the company’s Alzheimer’s program and advanced Alzheimer’s and aging issues through development of commercial strategy and advocacy with international organizations, nongovernmental organizations, nonprofits, and other key stakeholders.

Read more

This Speaker's Sessions

Tuesday Oct. 17
2:30–3:15 PM ET
Watch Replay
Now Live!

New Technologies for Early Detection and Diagnosis of Alzheimer’s

Scaling up technologies for early detection of Alzheimer’s pathology and cognitive impairment promises to transform the global response to Alzheimer’s disease. Digital biomarkers and fluid biomarkers (ranging from cerebrospinal fluid to blood) to detect the disease are advancing rapidly in clinical practice and will enable a more simple, timely, and accurate Alzheimer’s diagnosis.  Key Question: What do these tools and technologies mean for patients and their doctors?

View SessionWatch Replay